Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Leading Diabetes Advocacy Groups Urge CDC to Include Americans with Diabetes in Those Prioritized for COVID-19 Vaccine Boosters

Americans with Diabetes

AAOS

Today, the American Diabetes Association® and 14 other leading voluntary health organizations and medical societies concerned with diabetes urged the Centers for Disease Control and Prevention (CDC) to consider the health risks people with diabetes are facing with COVID-19 as the agency develops guidance on special patient populations who may benefit from additional COVID-19 vaccine doses. Combined, these groups advocate on behalf of the 122 million Americans with diabetes and prediabetes.

This week, it was announced that the Food and Drug Administration (FDA) and CDC will be releasing guidance recommending that immunocompromised Americans would benefit from additional doses of the COVID-19 vaccine. This population would include those who are disproportionately at risk of contracting COVID, including cancer patients, transplant patients, and others.

In a letter led by the American Diabetes Association (ADA) to the CDC, the groups urge CDC to additionally consider patient populations who suffer the worst health outcomes after contracting COVID-19, like patients with diabetes who, to date, have made up approximately 40 percent of all COVID-19 related mortalities. The letter points to other disproportionately poor outcomes from COVID-19 that people with diabetes experience, including significantly greater risk from being hospitalized and the fact that diabetes is one of the most frequently identified underlying health conditions reported in Americans contracting COVID-19.

“There are two issues here,” said Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA. “First, you must consider the population of patients who are most at risk from contracting the COVID-19 virus. Thus far, this has been the focus of the CDC and the FDA.”

Dr. Gabbay continued, “However, we would encourage the agencies to ensure that we’re making available additional protections for those patients who we know suffer the worst outcomes from COVID-19. This includes Americans with diabetes, who would benefit tremendously from protections offered by additional COVID-19 doses.”

On Friday, the CDC’s Advisory Committee on Immunization Practices is set to hold a hearing on this issue.

 

Other News of Interest

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

Mark Turco, MD Appointed President of Xenter’s Medical Technologies Business Unit

Dr. Turco brings a wealth of skill and insight to Xenter and possesses the clinical knowledge and industry experience.

Kevin L. Hagan to Serve as Next President/CEO of The PAN Foundation

As president and CEO, Hagan will lead the PAN Foundation's strategy and oversee its safety net programs and advocacy initiatives.

By using this website you agree to accept Medical Device News Magazine Privacy Policy